Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
Stefano Gonnelli1, Roberto Petrioli21Department of Internal Medicine, Endocrine-Metabolic Science and Biochemistry, University of Siena, Italy (Dir. R. Nuti.); 2Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Italy (Dir. G. Francini)Abstract: The third-gene...
Guardado en:
Autores principales: | Stefano Gonnelli, Roberto Petrioli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a64a60dcabf4cc6a248eee57f1efdcd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
por: Krstić Predrag, et al.
Publicado: (2021) -
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
por: Yee AJ, et al.
Publicado: (2012) -
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani D, et al.
Publicado: (2021) -
Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions
por: Maura Harrigan, et al.
Publicado: (2021) -
Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis
por: Xue-Ying Zhu, et al.
Publicado: (2021)